Name: Aligos Therapeutics, Inc. (ALGS) Financial Statements
Creator: FinSpry

Aligos Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Aligos Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	3.95	15.53	13.91	4.36	0.00
Cost of Revenue	70.27	73.04	85.08	104.15	79.89
Gross Profit	-66.32	-57.51	-71.17	-99.79	-79.89
Operating Expenses
Research & Development	70.27	73.04	85.08	104.15	79.89
Selling, General & Administrative	22.83	30.62	26.41	28.53	17.94
Operating Expenses	22.83	103.66	111.49	28.53	97.83
Operating Income	-89.15	-88.13	-97.58	-128.32	-97.83
Other Income/Expense
Interest Income	1.67	1.24	1.64	0.24	1.26
Interest Expense	0.00	0.00	0.00	0.00	-0.24
Other Income/Expense	-43.39	-2.17	-13.91	-0.10	-0.07
Income
Income Before Tax	-130.88	-86.88	-95.94	-128.19	-108.38
Income Tax Expense	0.33	0.80	0.11	0.14	0.16
Net Income	-131.21	-87.68	-96.05	-128.33	-108.54
Net Income - Continuous Operations	-131.21	-87.68	-96.05	-128.33	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-88.13	-85.06	-93.91	-125.30	-94.51
EBIT	-89.15	-88.13	-97.58	-128.32	-97.83
Depreciation & Amortization	1.03	3.07	2.30	3.02	2.70
Earnings Per Share
Basic EPS	-21.00	-34.00	-2.00	-80.00	-11.00
Diluted EPS	-21.00	-34.00	-2.00	-80.00	-11.00
Basic Shares Outstanding	6.26	2.56	42.70	1.59	9.99
Diluted Shares Outstanding	6.26	2.56	1.71	1.59	9.99